Immune correlates of vaccine protection against HIV-1 acquisition - Test2 - elhamkhani - TriplyDB

Immune correlates of vaccine protection against HIV-1 acquisition

Immune correlates of vaccine protection against HIV-1 acquisition

http://www.wikidata.org/entity/Q26778573

about

Approaches to preventative and therapeutic HIV vaccines Recent update in HIV vaccine development Humoral Dysregulation Associated with Increased Systemic Inflammation among Injection Heroin Users Modeling HIV vaccine trials of the future.Lessons learned from human HIV vaccine trials.Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques.Combining biomedical preventions for HIV: Vaccines with pre-exposure prophylaxis, microbicides or other HIV preventions Dendritic Cell Targeting Effectively Boosts T Cell Responses Elicited by an HIV Multiepitope DNA Vaccine.Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies.Increased, durable B-cell and ADCC Responses Associated with T-helper Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site.Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination.Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.Advances in clinical immunology in 2015.CD4 T-Cell Responses in Primary HIV Infection: Interrelationship with Immune Activation and Virus Burden.A novel polyepitope vaccine elicited HIV peptide specific CD4+ T cell responses in HLA-A2/DRB1 transgenic mice.Protection against HIV Acquisition in the RV144 Trial.A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.The quest for an antibody-based HIV vaccine.Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers.High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5α-Restrictive Macaques.Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.The Landscape of Targeted Immune Responses in the HIV-1 Vaccine Field.A systems approach to HIV-1 vaccines.Non-neutralizing antibody functions for protection and control HIV in humans and SIV and SHIV in non-human primates.Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization.HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees.Beyond binding: antibody effector functions in infectious diseases.HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.Developing an HIV vaccine.Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones.A novel strategy to adapt SHIV-E1 carrying env from an RV144 volunteer to rhesus macaques: coreceptor switch and final recovery of a pathogenic virus with exclusive R5 tropism.HIV Vaccination: A Roadmap among Advancements and Concerns.

P2860

Q26764851-26FDDE36-CD1C-439F-813E-1CB81B3EA1EB Q26766628-4DE97FB1-DC06-416B-A550-585972C5C86F Q28552355-21B05BC2-8E1F-4B98-8B3B-7443B6BB8D3C Q30393307-B0565B49-41F1-40AA-A8D9-42A6D66C33A5 Q33557844-8EF17992-7E24-497C-A750-3AE3766BD9ED Q33594304-6354FD2F-2123-4B99-A668-9849D43159B6 Q34537743-FACE4060-2E3D-4F08-BC8B-3C4F5E3FBBE9 Q34540352-BBC22003-F477-475E-B85E-7FEC26F4E9F5 Q36118373-FC14B05C-2B68-4293-BE40-2A35B3EE58B9 Q37253001-5E7A2C3A-5CC2-4367-88A1-1105F16640B9 Q37469197-EF1B7E30-D4D2-477D-AD2F-F6AB9A037182 Q37561407-2C9A5626-3DBF-4701-B27F-2B3A0C49C7C2 Q37628515-C20C8D9C-F6FF-4414-80EC-27F6FB89C1D4 Q37634061-03460746-7E9F-44BA-87FF-FFDFD822AB7D Q38658529-5C50DC79-476F-4BAB-93B2-21BC72D90A7C Q38702368-851EFD7B-694D-4CFC-917A-CFB3FCF7C2E2 Q38716886-FCDF271F-458C-4CC1-A787-3F1531EDBFF0 Q39033205-4AAAA070-99B2-4A7E-9C40-0096688D7270 Q39285671-FE45144C-AE98-4EF8-B223-4AB5F5488D31 Q40061333-B8A8F15A-FB75-439F-859A-543B62E44F52 Q40137608-F9FD8BCB-F056-4BA3-AB53-4FEB529EAE38 Q40220988-BCF4147C-E621-441E-987D-C5E44577DB37 Q40332276-61E56523-26B0-4131-9125-436514E2EA79 Q40354016-58DB9DEF-3752-432F-AD0D-2A0688DA887E Q40393896-4529878E-61D7-4E61-940E-37D00BF32C2F Q40523370-3FEE6E60-F37F-43E0-A2B5-78093E458A1A Q40579418-688574A4-F5D8-4447-8E3C-29088F6E0942 Q40634945-BD792309-EEB4-409B-BCD2-EECF5B56CC80 Q40991319-5D48CD02-1DEE-4AF1-8766-02C3FEE82D88 Q42368984-35B212FC-F0E0-471B-B259-403645D9FC02 Q46633111-4AC2D33B-C149-46F3-8FA9-63B72CA43345 Q47364595-E23B4BA8-74F7-48D9-89AF-DC7145C8C3C1 Q47547483-CE15F8E7-B62D-461F-AF16-97ABC0D4B677 Q47602559-875BDB91-E6AE-4F76-A1A3-A3FBA1E5E67E Q47616308-01AFA15F-7568-4915-AF95-B33A188F4F19 Q47852386-4C0DFC95-74EF-435D-AD91-9F33CF8B15EA Q52568669-06A51BAA-9DC9-4271-AF44-8BE237E27C32 Q52660832-FB4BB77B-1AE9-497B-BB34-52E7239C7D2E Q54216786-1D8780C1-0A01-4983-84A3-B4CEC8B8AE3A Q54232567-4EA87518-7088-482E-89A1-2CDA71C9450E

P2860

Immune correlates of vaccine protection against HIV-1 acquisition

http://www.wikidata.org/entity/Q26778573

description

2015 nî lūn-bûn

@nan

2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Immune correlates of vaccine protection against HIV-1 acquisition

@ast

Immune correlates of vaccine protection against HIV-1 acquisition

@en

Immune correlates of vaccine protection against HIV-1 acquisition

@nl

type

label

Immune correlates of vaccine protection against HIV-1 acquisition

@ast

Immune correlates of vaccine protection against HIV-1 acquisition

@en

Immune correlates of vaccine protection against HIV-1 acquisition

@nl

prefLabel

Immune correlates of vaccine protection against HIV-1 acquisition

@ast

Immune correlates of vaccine protection against HIV-1 acquisition

@en

Immune correlates of vaccine protection against HIV-1 acquisition

@nl

P1433

Q26778573-B79A9803-DF1D-43E9-B2F0-C42A9597CCC4

P1476

Q26778573-244FEB47-3B02-4DDA-96DF-A16AA1FE04EF

P2093

Q26778573-72171852-5BF8-4CE9-8A8A-33AA9DD2504D

Q26778573-8D4A315B-0C48-40E2-A145-7A1AD8CEB5E3

Q26778573-A5CC28C3-6EF7-4027-874D-0E44F032E00A

P2860

Q26778573-0017D234-4F3E-4745-8A5E-1152622794A2

Q26778573-00B30560-13DC-4565-AD58-F1E0F086015E

Q26778573-03C77F5E-6AF3-4372-BAFD-17EDF6AC3659

Q26778573-0B7DB124-D493-4C0B-BA4E-682B4B75CF80

Q26778573-0C836010-64A7-4B64-A1E0-12FB4BAB1B6C

Q26778573-1992AB7C-AC99-45C1-947F-096C44A3E42B

Q26778573-288D120F-E3C2-4036-805D-AD3D6DAB3048

Q26778573-28C752DC-372C-422D-8B0D-F8F4805AFB12

Q26778573-34FBB5F9-6F0D-45CC-B6DD-956201B84B75

Q26778573-3BA95F11-4436-41C4-B825-331C85149941

P304

Q26778573-DCDB8C58-1C01-4CA1-B7B2-94BEC0E28D7A

P31

Q26778573-5F9774F2-74F9-4E89-996F-C6B86CF89FE5

P3181

Q26778573-DC16B58C-42BA-4243-B19F-0D02B0BA7F43

P356

Q26778573-B4ED5E1C-A315-4C66-AA0A-DADD16794949

P407

Q26778573-1B3E9217-0DC1-432E-A9D2-120C15B9B783

P433

Q26778573-59D9DA1D-1945-4D68-9BAF-350EC365C491

P478

Q26778573-BD97943C-0BB1-447A-92CE-29E5A5A98CEB

P50

Q26778573-672DF7E5-B0F3-48CE-A04C-6AE9DB0661F5

Q26778573-F205DCDA-C821-40C1-8532-C171C34C8846

Q26778573-FC132E85-E1E9-4AB7-9A61-F3ADFB8E6F1E

P577

Q26778573-74B1445E-A432-407A-A6AA-8A4E16DC9D4A

P698

Q26778573-5D57A497-1A9B-46E9-84B0-95B9D9BBD6C2

P932

Q26778573-8826D6A1-E363-44EA-9794-2B257F77E7E2

P3181

P356

SCITRANSLMED.AAC7732

P1433

Science Translational Medicine

P1476

Immune correlates of vaccine protection against HIV-1 acquisition

@en

P2093

Georgia D Tomaras

http://www.w3.org/2001/XMLSchema#string

Lawrence Corey

http://www.w3.org/2001/XMLSchema#string

Peter B Gilbert

http://www.w3.org/2001/XMLSchema#string

P2860

COMPASS identifies T-cell subsets correlated with clinical outcomes

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Nonreplicating vectors in HIV vaccines.

HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.

P304

310rv7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

258177

http://www.w3.org/2001/XMLSchema#string

P356

10.1126/SCITRANSLMED.AAC7732

http://www.w3.org/2001/XMLSchema#string

P407

P433

310

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Pantaleo

P577

2015-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26491081

http://www.w3.org/2001/XMLSchema#string

P932

4751141

http://www.w3.org/2001/XMLSchema#string